DESIGN, OPTIMIZATION, AND EVALUATION OF ACYCLOVIR FAST DISSOLVING TABLETS EMPLOYING STARCH PHTHALATE – A NOVEL SUPERDISINTTEGRANT

SANTOSH KUMAR R*, ANNU KUMARI

Department of Pharmaceutics, GITAM Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, India.

Email: drsantoshrada@gmail.com

Received: 28 August 2019, Revised and Accepted: 27 September 2019

ABSTRACT

Objective: The objective of the present research was to prepare starch phthalate (a novel superdisintegrant) and to optimize and formulate acyclovir fast dissolving tablets employing 23 factorial design using starch phthalate as superdisintegrant.

Materials and Methods: Drug excipient compatibility studies such as Fourier-transform infrared spectroscopy, differential scanning calorimetry, and thin-layer chromatography were carried out to check the drug interaction between acyclovir and starch phthalate. The direct compression method was used for tablet preparation. Prepared tablets were then evaluated for hardness, friability, drug content, disintegration time, water absorption, and wetting time, in vitro dissolution studies. Response surface plots and contour plots were also plotted to know the main effects and interaction effects of independent variables (starch phthalate [A], croscarmellose sodium [B], and crospovidone [C] on dependent variables [disintegration time and drug dissolution efficiency in 1 min]) and stability studies were also done.

Results: Tablets of all formulations were of good quality concerning drug content (100±5%), hardness (3.6–4.0 kg/cm²), and friability (<0.16%). In all formulations, formulation F8 found to be optimized formulation with least disintegration time 9±3 s, less wetting time 10±0.17 s, and enhanced dissolution rate in 1 min, i.e., 99.92±0.11 as compared to other formulation.

Conclusion: From the research, it was concluded that on combination with crospovidone (5%) and croscarmellose sodium (5%), starch phthalate (10%) enhanced the dissolution efficiency of the drug. Hence, starch phthalate can be used as a novel disintegrant in the manufacturing of fast dissolving tablets.

Keywords: Fast dissolving tablets, Superdisintegrant, Starch phthalate, Acyclovir, Dissolution efficiency.

INTRODUCTION

Fast dissolving tablets are solid oral dosage forms which disintegrate in the mouth as it comes in contact with saliva and absorbs some amount through the mouth and some in the stomach. Furthermore, named as, orally disintegrating tablets or mouth dissolving tablets [1,2]. The specific property which differentiates fast dissolving tablets from conventional tablets is their quick disintegration in mouth and drug dissolution within 5 min. It shows enhanced drug dissolution and has advantages over both conventional tablets and liquid dosage forms [3,4]. Fast dissolving tablets are not only preferred choice for patients having difficulty in swallowing but also the first choice for people with no access to water at the time of administration [5].

Acyclovir falls under BCS Class III drug with poor bioavailability (10–30%). It is an antiviral drug and used against herpes virus (HSV-1 and HSV-2) by retarding its growth and spread in the body [6].

In present research work by preparing fast dissolving tablets of acyclovir with novel superdisintegrant, starch phthalate and with other superdisintegrants (croscarmellose sodium, and crospovidone), the oral bioavailability of acyclovir can be enhanced safely with fewer side effects. Tablets were prepared as per 2³ factorial designs and evaluated for their hardness, friability, drug content, in vitro drug dissolution, and stability studies.

MATERIALS AND METHODS

Materials

Acyclovir, crospovidone, croscarmellose sodium, starch, and potato starch were purchased from Yarniw chemicals, Mumbai. Phthalic anhydride, dimethyl sulfoxide, acetone, and isopropanol were obtained from Finar Chemicals Ltd., Ahmedabad. Ethanol was bought from Changshu Yangyun Chemicals, China. Microcrystalline cellulose was procured from Qualigens fine chemicals, Mumbai. Magnesium stearate and talc were purchased from Molychem, Mumbai. Starch phthalate melting point checked by melting point apparatus [9].

Preparation of a novel superdisintegrant starch phthalate

Starch phthalate was prepared by esterification reaction using potato starch and phthalic anhydride as in previous research work. Esterification reaction was used for the preparation of superdisintegrant [7,8]. The steps wise procedure of the preparation of starch phthalate is explained in Fig. 1.

Characterization of starch phthalate

The novel superdisintegrant starch phthalate prepared was evaluated for the following parameters as given in Fig. 2.

Solubility

Solubility of prepared superdisintegrant (starch phthalate) was tested both in aqueous solvents (distilled water, buffer of potential of hydrogen [pH] 1.2, 4.5, and 7.4) and organic solvents (petroleum ether, alcohol, acetone, dichloromethane, and chloroform) and noted down accordingly [9].

pH

About 1% slurry of the starch phthalate was prepared in distilled water and pH was checked by pH meter [9].

Melting point

Starch phthalate melting point checked by melting point apparatus [9].
Viscosity
1% slurry of the starch phthalate was prepared in distilled water and pH was checked by pH meter [9].

Swelling index
200 mg of starch phthalate was added into two graduated test tubes having liquid paraffin and distilled, respectively, and mixed well. The prepared dispersion was allowed to stand for 12 h and then washed with isopropyl to remove any unwanted phthalic anhydride if present. Then, the product was mixed with aceton for 15 min and then washed with isopropyl to remove any unwanted phthalic anhydride if present. After washing the resultant starch phthalate was kept in oven at 60°C until it gets dried. The product obtained was ground and sieved (# 120).

Test for gelling property
About 7% dispersion of potato starch and starch phthalate in distilled water was prepared and checked for its gelation property. Dispersions were allowed to heat in a water bath at 1000°C for 30 min [9].

Particle size
The particle size analysis was performed by microscopic method [9].

Density
The density (g/cc) was measured by liquid displacement process using benzene as liquid [9].

Bulk density
In a 50 ml clean and dry measuring cylinder, accurately weighed amount of sample was transferred and volume of packing was noted down. Tapped that cylinder 50 times on a plane surface and tapped volume of packing was noted down. Loose bulk density and tapped bulk density are calculated as per the formula given below [10].

\[
LBD = \frac{\text{Mass of powder}}{\text{Volume of packing}}
\]

\[
TBD = \frac{\text{Mass of powder}}{\text{Tapped volume of packing}}
\]

Percentage compressibility index
Carr’s compressibility index of the powder blend was calculated by the following formula [11].

\[
\% \text{Carr’s Index} = \frac{\text{Tapped bulk density} - \text{Loose bulk density}}{\text{Tapped bulk density}} \times 100
\]

Angle of repose
Angle of repose is the highest angle possible between the surface of a mass of powder or granules and the horizontal plane [11]. Angle of repose is measured by applying the next equation;

\[
\tan \theta = \frac{h}{r}
\]

\[
\theta = \tan^{-1} \left( \frac{h}{r} \right)
\]

Where \( \theta = \) Angle of repose; \( h = \) Height of pile; \( r = \) Radius of pile.

Fourier-transform infrared spectroscopy (FTIR)
FTIR spectra of potato starch and starch phthalate were recorded on samples prepared in potassium bromide (KBr) disks using a BRUKER FT–IR, (Tokyo, Japan). The preparation of samples was performed in KBr disks by means of a hydrostatic press at 6–8 tons pressure [12]. The sample was scanned under the range of 500–4000 cm\(^{-1}\).

X-ray diffraction
Diffraction pattern of starch phthalate was recorded with an X-ray diffractometer (Analytical Spectra’s Pvt. Ltd., Singapore). X-ray diffraction was performed at room temperature (30°C) with a diffractometer; target, Cu (\( \lambda = 1.54 \) A), filter, Ni; voltage, 45 kV; current 40 mA; time constant 10 mm/s; scanning rate 2°/min; and measured from 10° to 35° at full scale 200 [13].

Drug-excipients compatibility studies
The compatibility of starch phthalate with the selected drug (acyclovir) was evaluated by differential scanning calorimetry (DSC), thin-layer chromatography (TLC), and FTIR studies.
withstand damage while handling and transportation. To find out the compression force, hardness test determines the ability of a tablet to withstand damage while handling and transportation. To find out the hardness of prepared tablets, Monsanto hardness tester was used and unit used to express is kg/cm² [15].

### Uniformity of weight

Weight variation of tablets is nothing but how the weight of each individual tablet is differed from the average weight of the 20 selected tablets. Randomly, 20 tablets were selected to determine the weight variation of the tablets, and average weight of 20 tablets and individual weight of each tablet were noted down [16].

### Friability

Friability also tells the ability of tablets to withstand pressure and damage while transportation from one place to other. Roche friabilator was used to determine friability of prepared tablets. At 25 rpm (revolutions per minute) tablets were rotated for 4 min or up to 100 revolutions. Then, the tablets were reweighed after removal of fines and the percentage of weight loss was calculated [17].

\[
F = \frac{100 \times W_{\text{initial}} - W_{\text{final}}}{W_{\text{initial}}}
\]

**Drug content uniformity**

Randomly, 10 tablets were selected and weighed. Tablets were powdered and weighed equivalent to 10 mg of acyclovir, were extracted into 0.1 N HCl buffer and filtered. The acyclovir content was calculated by measuring the absorbance using spectrophotometric method at 254 nm after appropriate dilution with 0.1 N HCl buffer. The drug content was measured as an average of three determinations [18].

### Wetting time

In a dry petri dish, tissue paper was placed having diameter of 10 cm. Carefully, 10 ml of the amaranth color solution was added to the petri dish. Before keeping a tablet, its weight was noted down and carefully in the center of the petri dish a tablet was kept. Observed carefully to note if it was wetted or not.
the wetting time of tablet. Here, time required for the tablet to reach the upper surface of the tablet was noted down as wetting time [19].

Water absorption ratio
Take a petri dish in which tissue paper folded twice was placed and carefully 6 ml of water was added to it. A tablet was kept on the tissue paper and allowed to wet completely. The wetted tablet was then weighed. Water absorption ratio R was determined using following equation [19].

\[ R = \frac{100 \times (W_t - W_w)}{W_w} \]

Where,
\( W_t \) = weight of tablet after water absorption
\( W_w \) = weight of tablet before water absorption.

In vitro disintegration time
Disintegration time for fast dissolving tablets was determined using United States Pharmacopeia (USP) disintegration apparatus 0.1 N HCl (hydrochloride) buffer. The volume of medium was 900 ml and temperature was 37±0.2°C. The time in second taken for complete disintegration of the tablet with no palatable mass remaining in the apparatus was determined [20].

In vitro dissolution studies
The in vitro dissolution rate study of acyclovir fast dissolving tablets was performed using 8 stage dissolution test apparatus (Electrolab TDT-08L) fitted with paddles (50 rpm) at 37±0.5°C, using 0.1 N HCl (hydrochloride) buffer (900 ml) as a dissolution media. 5 ml of the samples were taken at definite time interval, filtered through 0.45 µ membrane filter, diluted, and assayed at 254 nm using an analytical technology T360 ultraviolet–visible double beam spectrophotometer. Cumulative percentage release was measured using standard absorbance from the calibration curve [21].

Response surface plot study
Optimization of the acyclovir fast dissolving tablets was done using 2³ factorial designs in which 3 factors each at two levels were evaluated. Starch phthalate (Factor A), croscarmellose sodium (Factor B), and crospovidone (Factor C) individual and combined effect were determined by response surface plot method [22].

A polynomial regression algorithm was used to rotate the independent variables to the response variables. The general first-order model and equation, they could be constructed from 2ⁿ experimental design is indicated in the following equation.

\[ Y = \beta_1 + \beta_2 A + \beta_3 B + \beta_4 C + \beta_{12} AB + \beta_{13} AC + \beta_{23} BC + \beta_{123} ABC \]

Where, \( Y \) is the measured response, \( \beta \) is the arithmetic mean response of 1 min, \( \beta_{12} \), \( \beta_{13} \), \( \beta_{23} \), \( \beta_{123} \) are coefficients for the corresponding factors and A, B, C, AB, AC, BC, and ABC are the percentages of starch phthalate, croscarmellose sodium, and crospovidone and interaction terms, respectively. The coefficients were calculated accordingly to the general formula given in equation.

\[ B = \Sigma Y/2^n \]

Where \( \beta \) is coefficient, X is the corresponding variable (A, B, and C), Y is the response value (disintegration time and dissolution efficiency in 1 min), and n is the level. The two levels of three factors employed in the experimental design are indicated in Table 2 and transformed design for analysis of responses of acyclovir fast dissolving tablets is shown in Table 3.

Stability studies
As per International Council for harmonization stability, guidelines stability studies are performed to check the changes in the quality of a drug substance or drug product by the effect of temperature, humidity, and light with time. Stability studies of F8 formulation were carried out. Tablets were packed in high-density polyethylene bottles and stored at 40±2°C and 75% RH for 6 months. By evaluating the stored tablets for drug content and drug release, tablet stability was determined after 6 months.

RESULTS AND DISCUSSION
The starch phthalate prepared was found to be fine, smooth, and free flowing amorphous powder. The physical and micromeritics properties of the starch phthalate are summarized in Table 4. It was insoluble in aqueous solvents and insoluble in organic solvents tested (methanol, petroleum ether, dichloromethane, and chloroform) the pH of 0.1% aqueous dispersion was 2.88.

Starch phthalate exhibited good swelling in water. The swelling index was 1200. All micrometric properties indicated good flow and compressibility needed for solid dosage form manufacturing. The density of starch phthalate was found to be 0.555 g/cc. The angle of repose and compressibility index showed good flow properties of starch phthalate.

Table 2: Levels of the three factors used in experimental design

| S. No. | Factors/Ingredients | Code | Level L1 | Level L2 |
|--------|---------------------|------|----------|----------|
| 1      | Starch phthalate    | A    | 5        | 10       |
| 2      | Croscarmellose sodium | B    | 0        | 5        |
| 3      | Crospovidone        | C    | 0        | 5        |

Factor A (starch phthalate), Factor B (croscarmellose sodium), Factor C (crospovidone)

Table 3: Transformed design for analysis of response of acyclovir FDTs

| S. No. | Formula code | A (%) | B (%) | C (%) |
|--------|--------------|-------|-------|-------|
| 1      | F1           | 5     | 0     | 0     |
| 2      | F2           | 10    | 0     | 0     |
| 3      | F3           | 5     | 5     | 0     |
| 4      | F4           | 10    | 5     | 0     |
| 5      | F5           | 5     | 0     | 5     |
| 6      | F6           | 10    | 0     | 5     |
| 7      | F7           | 5     | 5     | 5     |
| 8      | F8           | 10    | 5     | 5     |

FDTs: Fast dissolving tablets

Table 4: Physical and micromeritics properties of the starch phthalate (novel superdisintegrant)

| Parameters          | Observation                      |
|---------------------|----------------------------------|
| Solubility          | Insoluble in all aqueous and organic solvents tested 2.08% |
| pH (potential of hydrogen) (1% w/v aqueous dispersion) | Charred at 325°C  |
| Melting point       | 1.08 cps                        |
| Viscosity           | (1% w/v aqueous dispersion)      | 65% No gelling and the swollen particles of starch phthalate separated from water, whereas in the case of starch, it was gelatinized and formed gel |
| Swelling index      |                                  | Moisture absorption 4.4% |
| Gelling property    |                                  | Particle size 158 μm (80/120 mesh) |
| Density             | 0.584 g/cc                      | Bulk density 0.555 g/cc |
| Angle of repose     | 27.4°                           | Compressibility index 14.23% |
The FTIR spectrum of potato starch and starch phthalate is given in Figs. 4 and 5. The presence of peaks of the absorption at 1691.57 cm⁻¹ characteristic peaks of ester, so from FTIR studies, it was concluded that starch phthalate (ester) was formed when potato starch was allowed to react with phthalic anhydride.

The X-ray diffraction pattern of starch phthalate not showed any peaks which indicates that the structure is completely amorphous. The disappearance of pink color in the ester test confirmed the presence of ester, i.e., starch phthalate. As the starch phthalate was amorphous, smooth, and free flowing powder and it had got all the characteristics of superdisintegrants, it was concluded that starch phthalate can be used as novel superdisintegrant in the formulation of fast dissolving tablets.

The compatibility of starch phthalate with the selected drug (acyclovir) was evaluated by DSC, FTIR, and TLC studies. The DSC thermograms of acyclovir and acyclovir with starch phthalate are shown in Figs. 6 and 7.

The DSC thermograms of acyclovir and aceclofenac with starch phthalate exhibited exothermic peaks at 251°C and 227.6°C, respectively. These melting peaks of acyclovir and acyclovir and starch phthalate are nearer to the melting points of acyclovir (230–260°C). The peaks observed in the FTIR spectrum of acyclovir with starch phthalate were absent in the FTIR spectrum of pure drug acyclovir.
in the DSC thermograms of acyclovir and acyclovir-starch phthalate mixtures correspond to the melting points of the respective drug. Thus, DSC study indicating no interactions between the selected drug (acyclovir) and starch phthalate.

The FTIR spectra of acyclovir and acyclovir and starch phthalate are shown in Figs. 8 and 9. The characteristic FTIR bands of acyclovir at 2926.01 cm\(^{-1}\) (C-H) and 3441.01 cm\(^{-1}\) (N-H) were all observed in the FTIR spectra of both acyclovir and acyclovir-starch phthalate. These FTIR spectra observations also indicated no interaction between starch phthalate and acyclovir.

TLC plate showing single spots of acyclovir and acyclovir-starch phthalate is shown in Fig. 10. Single spots were observed in the case of pure drug as well as their mixtures with starch phthalate. The close agreement of the Rf value of the acyclovir and acyclovir-starch phthalate as given in Table 5 indicated no interaction between the drug and starch phthalate.

Thus, the results of DSC, FTIR, and TLC indicated no interaction between the selected drug (acyclovir) and starch phthalate, the new superdisintegrant. Hence, starch phthalate can be used as a superdisintegrant in the design of fast dissolving tablets of the selected drug.

Hardness of tablets from all batches was found to be in the range of 3.6–4.0 kg/cm\(^2\). All tablets are having enough hardness indicating good strength with a capability to resist physical and pre-functional stress conditions during handling as reported in earlier literature [23].

All the tablets exhibited acceptable friability as weight loss on the friability test was <0.15% in all formulations. As per Indian Pharmacopeia (IP), percent friability below 1% is an indication of good mechanical resistance of the tablets. Thus, it was proved that tablets could withstand the pressure, mechanical shocks during handling, transportation, storage, and manufacturing processes as per literature survey [21,22,23].

All formulations were found to be having drug content within 100±5% of the labeled amount. Hence, it can be concluded that all the formulations are having an accurate amount of drug distributed uniformly in powder mass and followed acceptable limits as per IP.

The in vitro disintegration time of all the tablets was found to be in the range of 9±0.6–48±0.5 s. F8 formulation was found with having least disintegration time of 9 s as compared to other formulation, the order of disintegration time in increasing order is F8<F7<F6<F5<F4<F3<F2<F1. Fast dissolving tablets prepared employed starch phthalate (novel superdisintegrant) showed disintegration time as compared to fast dissolving tablets prepared using combination of known superdisintegrants such as croscarmellose sodium, sodium starch glycolate, and crospovidone and by wet granulation method using superdisintegrant as reported in earlier literature [25,26].

The water absorption ratio was between 42.5±0.01 and 68.0±0.04. The wetting time was found between 10±0.17 and 49±0.25. Results of hardness, friability, drug content, disintegration time, wetting time, and water absorption ratio are given in Table 6. The water absorption ratio and wetting time of all formulations are shown in Fig. 11. Formulation F8 containing 10% starch phthalate, 5% crospovidone, and 5% croscarmellose sodium showed less wetting time, i.e., 10±0.17 s as compared to other formulations. Fast dissolving tablets using starch phthalate as superdisintegrant has shown less wetting time as compared to fast dissolving tablet prepared using solid dispersion technique as compared with literature survey [10,27].

In vitro dissolution test was carried out in USP Type II paddle apparatus. The dissolution rate depends on wetting time of the disintegrant. Among all the formulations, F8 has less wetting time and has greater dissolution limits as per IP.

### Table 5: RF value of the acyclovir and their mixture (1:1) with starch phthalate

| S. No. | Product                  | RF value |
|--------|--------------------------|----------|
| 1.     | Acyclovir                | 0.7      |
| 2.     | Acyclovir-starch phthalate | 0.65    |

RF: Retardation factor

### Table 6: Physical properties: Hardness, friability, and drug content of acyclovir fast dissolving tablets

| Formulation | Hardness (kg/cm\(^2\)) n±S.D | Friability (%) n±S.D | Drug content (mg/tab) n±S.D | Disintegration time (s) n±S.D | Wetting time (s) n±S.D | Water absorption ratio (%) n±S.D |
|-------------|-------------------------------|----------------------|------------------------------|-------------------------------|------------------------|---------------------------------|
| F1          | 3.9±0.01                      | 0.12±0.013           | 198±0.71                     | 45±0.3                       | 49±0.25                | 48.9±0.01                       |
| F2          | 3.6±0.03                      | 0.13±0.015           | 198±0.79                     | 27±0.2                       | 43±0.21                | 51.5±0.23                       |
| F3          | 4.0±0.01                      | 0.14±0.012           | 199±0.63                     | 24±0.1                       | 42±0.23                | 68±0.04                         |
| F4          | 3.8±0.04                      | 0.12±0.014           | 198±0.55                     | 38±0.5                       | 36±0.19                | 51.4±0.22                       |
| F5          | 3.7±0.03                      | 0.14±0.014           | 198±0.56                     | 20±0.4                       | 20±0.12                | 50±0.05                         |
| F6          | 3.9±0.01                      | 0.15±0.012           | 198±0.18                     | 14±0.2                       | 17±0.18                | 52.9±0.52                       |
| F7          | 3.7±0.02                      | 0.14±0.014           | 198±0.57                     | 12±0.4                       | 15±0.11                | 58±0.04                         |
| F8          | 4.0±0.04                      | 0.12±0.013           | 199±0.11                     | 9±0.3                        | 10±0.17                | 42.5±0.01                       |
| F9          | 3.9±0.01                      | 0.15±0.012           | 198±0.11                     | 59±0.2                       | 29±0.19                | 31.4±0.01                       |

*SD Standard Deviation from mean, n=3
In vitro dissolution studies were carried out for all the formulations and dissolution profile of formulations F1-F4 is shown in Fig. 12 and of formulations F5-F8 is shown in Fig. 13. Percent dissolved in 1 min (PD₁) was found to be more in F8 formulation which consists of 10% starch phthalate, 5% croscarmellose sodium, and 5% crospovidone. The same was in the case of dissolution efficiency in 1 min (DE₁%). Dissolution parameters of acyclovir fast dissolving tablets are given in Table 7. The PD₁ and DE₁% reveal that starch phthalate was effective at 10% starch phthalate, 5% croscarmellose sodium, and 5% crospovidone when the formulations were made by direct compression using these superdisintegrants.

Response surface plots study
The response surface plots and contour plots reveal that as the concentration of starch phthalate (Factor A), croscarmellose sodium (Factor B), and crospovidone (Factor C) increases, disintegration time decreases. Response surface plots indicate we can see the effects of Factor A (starch phthalate) and Factor B (croscarmellose sodium) on disintegration time and it was determined from contour plot that a less disintegration time can be obtained with Factor A (starch phthalate) level range between 5 and 6% and Factor B (croscarmellose sodium) level range from 4 to 5% as shown in Fig. 14.

Fig. 11: Wetting time of acyclovir fast dissolving tablets prepared by employing starch phthalate (novel superdisintegrant) and other known superdisintegrants

Fig. 12: Dissolution profile of acyclovir fast dissolving tablets of formulation F1 to F4 employing starch phthalate
Table 7: Dissolution parameters of acyclovir fast dissolving tablets formulated employing starch phthalate

| Parameters                  | F1    | F2    | F3    | F4    | F5    | F6    | F7    | F8    | F9    |
|-----------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| PD1 (%)                     | 76.53 | 88.58 | 94.96 | 45.35 | 85.74 | 72.28 | 97.79 | 99.92 | 36.85 |
| DE1 (%)                     | 70    | 81    | 87.5  | 37.5  | 80    | 65    | 90    | 91    | 30    |
| Increase in DE1 (%) no of folds | 2.3  | 2.7   | 2.91  | 1.25  | 2.66  | 2.16  | 3     | 3.03  | -     |
| K (min⁻¹)                   | 0.541 | 2.171 | 0.884 | 0.785 | 1.948 | 0.863 | 3.813 | -     | 0.141 |
| Increase in K (min⁻¹) no of folds | 3.8  | 15.3  | 6.2   | 5.5   | 13.8  | 6.1   | 27    | -     | -     |

*SD standard deviation from mean, n=3, PD1: Percent dissolved in 5 min, DE1%; Dissolution efficiency in 1 min, K1: First order rate constant
level range between 5 and 6% and Factor B (croscarmellose sodium)
level range 4 and 5%.

The effects of Factor B (croscarmellose sodium) and Factor C
(crospovidone) are shown in Fig. 18. The contour plots were found to be
almost linear indicating the linear relationship between croscarmellose
sodium and crospovidone. It was determined from the contour plot
that more dissolution efficiency in 1 min can be obtained with Factor
B (croscarmellose sodium) level range between 4 and 5% and Factor C
(crospovidone) level range 4 and 5%.

The effects of Factor A and Factor C are shown in Fig. 19. The contour
plots were found to be linear indicating the linear relationship between
starch phthalate and crospovidone. It was determined from the
contour plot more dissolution efficiency in 1 min can be obtained in
Factor A (starch phthalate) level range between 5 and 6% and Factor C
(crospovidone) level range between 4 and 5%.

### Table 8: Drug profile of acyclovir fast dissolving tablets of
formulation, F8 before and after 6 months storage for stability
testing

| Time (min) | Before storage | After 6 months |
|------------|----------------|----------------|
| 1          | 99.9±0.11      | 97.5±0.11      |

Fig. 16: (I) Response plot II (contour plot) of acyclovir fast dissolving tablets (effect of starch phthalate and crospovidone on
disintegration time in 1 min)

Fig. 17: (I) Response plot II (contour plot) of acyclovir fast dissolving tablets (effect of starch phthalate and croscarmellose sodium on
dissolution efficiency in 1 min)

Fig. 18: (I) Response plot II (contour plot) of acyclovir fast dissolving tablets (effect of croscarmellose sodium and crospovidone on
dissolution efficiency in 1 min)
Stability study
No visible changes were observed in the fast-dissolving tablets after storage. The drug dissolved from the fast-dissolving tablets were evaluated before and after storage in each case. No significant difference (p<0.05) was observed in the percent drug content before and after storage for 6 months. The drug dissolution of the acyclovir fast-dissolving tablets of formulation F8 before and after storage is given in Table 8. The drug dissolution characteristics of the formulation tested remained unaltered during the storage period. The results, thus, indicated that the drug content and drug release rate of the fast-dissolving tablets formulated employing starch phthalate were quite stable.

CONCLUSION
In present research work, starch phthalate a novel superdisintegrant was prepared using potato starch and phthalic anhydride. Acyclovir fast dissolving tablets prepared by direct compression method using 2 factorial designs were found of good quality and passed all evaluation tests such as hardness, friability, disintegration time, in vitro drug release, and stability and found to be suitable as fast-dissolving tablets. From the present investigation, it was found that in combination of croscarmellose sodium (5%), crospovidone (5%), and starch phthalate (10%) showed more dissolution efficiency in 1 min. Thus, starch phthalate found to be an effective superdisintegrant for the preparation of fast dissolving tablets.

ACKNOWLEDGMENT
The authors are thankful to GITAM Institute of Pharmacy, Visakhapatnam, for providing the facility to carry out the work successfully.

CONFLICTS OF INTEREST
The authors confirm that the article content has no conflicts of interest.

AUTHORS’ CONTRIBUTIONS
All the authors contributed equally.

REFERENCES
1. Roy A. Orodispersible tablets: A review. Asian J Pharm Clin Res 2016;9:19-26.
2. Masih A, Kumar A, Singh S, Tiwari AK. Fast dissolving tablets: A review. Int J Curr Pharm Res 2017;9:8-18.
3. Kumare MM, Marathe RP, Kawade RM, Ghante MH, Shendarkar GR. Design of fast dissolving tablet of atenolol using novel co-processed superdisintegrant. Asian J Pharm Clin Res 2013;6:81-5.
4. Smita SA, Saudagar RB, Mayuri SS. Review: Fast dissolving tablet. Int J Curr Pharm Res 2018;10:5-12.
5. Chauhan K, Solanki R, Sharma S. A review on fast dissolving tablet. Int J Appl Pharm 2018;10:1-7.
6. Tavakoli N, Varshosaz J, Dorkoosh F, Motaghi S, Tamaddon L. Development and evaluation of a monolithic floating drug delivery system for acyclovir. Chem Pharm Bull (Tokyo) 2012;60:172-7.
7. Kumar RS, Mudili S. Synthesis and characterisation of starch glutamate as a novel superdisintegrant. J Drug Deliv Ther 2019;9:100-3.
8. Kumar RS, Yagnesh TN. Optimization of starch oxalate as a novel superdisintegrant in fast dissolving systems of poorly soluble drugs. J Drug Deliv Ther 2019;9:185-95.
9. Kumar RS, Yagnesh TN. Synthesis, characterization and evaluation of starch xanthate as a superdisintegrant in the formulation of fast dissolving tablet. Int J Appl Pharm 2018;10:249-58.
10. Bhide P, Nachinolkar R. Formulation development and characterisation of meclizine hydrochloride fast dissolving tablets using solid dispersion technique. Int J Appl Pharm 2018;10:141-6.
11. Dhahir RK, Al-Kotaji M. Formulation of orally disintegrating tablets of cinnarizine by using direct compression method. Int J Appl Pharm 2019;11:117-23.
12. Shrvani B, Rao NG. Formulation and evaluation of fast dissolving tablets of montelukast sodium using co-processed superdisintegrants. Int J Drug Dev Res 2018;6:125-34.
13. Ajit Shankarao K, Dhatiysheel Mahadeo G, Pankal Balavantrao K. Formulation and in-vitro evaluation of orally disintegrating tablets of olanzapine-2-hydroxypropyl-β-cyclodextrin inclusion complex. Iran J Pharm Res 2019;9:335-47.
14. Preetshi GB, Banerjee S, Shivakumar HN, Kumar M. Formulation of fast-dissolving tablets of doxazosin mesylate drug by direct compression method. Int J Appl Pharm 2017;9:22-8.
15. Bhavani PD, Rao NG. Formulation and evaluation of valsartan fast disintegrating tablets by vacuum drying technique. Asian J Pharm Clin Res 2016;9:73-9.
16. Nagajyothi B, Babu MK. Design and development of glipizide fast dissolving tablets using natural gum superdisintegrant. Asian J Pharm Clin Res 2014;7:144-8.
17. Movva B, Kumar DL, Kumar KM. Formulation and evaluation of fast dissolving tablets of ramitidine hydrochloride by hole technology. Asian J Pharm Clin Res 2013;6:143-7.
18. Manimaran V, Damodhanar N. Development of fast dissolving tablets of amloidine besylate by solid dispersion technology using poloxamer 407 and poloxamer 188. Asian J Pharm Clin Res 2017;10:135-41.
19. Kumar RS, Ghosh A. Design, optimisation and evaluation of piroxicam fast dissolving tablets employing starch tartrate-a new superdisintegrant. Int J Appl Pharm 2019;11:89-97.
20. Parfait N, Rani KC, Charles N, Goevanny V. Preparation and evaluation of atenolol-β-cyclodextrin orally disintegrating tablets using co-process crosipovidone-sodium starch glycolate. Int J Appl Pharm 2018;10:190-4.
21. Remya PN, Saraswathi TS, Sangeetha S, Damodhanar N, Kavitha R. Formulation and evaluation of immediate release tablets of acyclovir. J Pharm Sci Res 2016;8:1258-61.
22. Bala R, Khanna S, Pawar PK. Formulation and optimization of fast dissolving intraoral drug delivery system for clobamaz using response surface methodology. J Adv Pharm Technol Res 2013;4:151-9.
23. Karpe M, Mali N, Kadam V. Formulation development and evaluation of acyclovir orally disintegrating tablets. J Appl Pharm Sci 2012;2:101-5.
24. Masih A, Tiwari AK. Formulation and evaluation of fast dissolving tablets of amoxycillin trihydrate and potassium clavulanate. Int J Curr Pharm Res 2017;9:48-58.
25. Chinnala KM, Vodithala S. Formulation development and evaluation of fast disintegrating tablets of cinatapride hydrogen tartarate by using direct compression technique. Int J Curr Pharm Res 2017;9:98-103.

26. Jain P, Gupta RN, Shrivastava S. Formulation and evaluation of mouth dissolving tablets of omeprazole. Int J Curr Pharm Res 2016;8:48-51.

27. Begum SK, Madhuri V, Padmalatha K. Design and evaluation of fast dissolving tablets of roflumilast solid dispersions. IJPSR 2019;10:599-101.